Position in ARGX
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,443,704
-$218,854 QoQ
Shares Held
1,977
0.0% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ARGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Callan Family Office, LLC holds $25,981,974 across 28 Biotechnology names. ARGX ranks #4 (5.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,036 | $6,981,575 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,262 | $6,815,093 | |
| 3 | GMAB |
Genmab A/S
|
55,047 | $1,476,911 | |
| 4 | ARGX |
Argenx SE
This page
|
1,977 | $1,443,704 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
7,358 | $1,391,029 | |
| 6 | TECH |
BIO-TECHNE Corp
|
20,483 | $1,070,441 | |
| 7 | INCY |
Incyte Corp
|
11,135 | $1,048,026 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
3,035 | $1,004,190 |
All Filings in ARGX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,443,704 | 1,977 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,662,558 | 1,977 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,001,606 | 1,358 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $800,371 | 1,452 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $214,255 | 362 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $396,060 | 644 | Shares | Sole | 2025-02-07 | |
| No filing history on record for this holder in this stock. | ||||||